{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:42:05Z","timestamp":1788975725048,"version":"build-2803163510"},"reference-count":38,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) may induce hepatitis B virus (HBV) reactivations in co-infected patients, whose dynamics and outcomes could depend on the phase of HBV infection. We investigated HBsAg and HBV-DNA kinetics in fifteen untreated HBeAg Negative Infection (ENI) (4F-11M, 62.1y) and eight Nucleos(t)ide Analogs (NAs) treated Chronic Hepatitis B (CHB) (3F-6M, 54.8y) with HCV co-infection, receiving DAAs-regimens including Sofosbuvir (13) or not (10). All achieved a sustained virologic response (SVR) and normalized alanine-aminotransferase (ALT). At the direct acting antivirals\u2019 (DAAs) baseline (BL), the HBV-DNA was undetectable (&lt;6 IU\/mL) in eight ENI and all CHB, the mean Log-HBsAg was lower in ENI than CHB (0.88 vs. 2.42, p = 0.035). During DAAs, HBV-DNA increased in untreated ENI by &gt;1 Log in five and became detectable in two. Accordingly, mean BL Log-HBV-DNA (0.89) increased at week-4 (1.78; p = 0.100) and at the end of therapy (1.57; p = 0.104). Mean Log-HBsAg decreased at week-4 in ENI (from 0.88 to 0.55; p = 0.020) and CHB (from 2.42 to 2.15; p = 0.015). After DAAs, the HBsAg returned to pre-treatment levels in CHB, but not in ENI (six cleared HBsAg). Female gender and SOF were associated with a greater HBsAg decline. In conclusion, HBV reactivations during DAAs in HCV co-infected ENI caused moderate increases of HBV-DNA without ALT elevations. The concomitant HBsAg decline, although significant, did not modify individual pre-treatment profiles.<\/jats:p>","DOI":"10.3390\/jcm11051406","type":"journal-article","created":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T20:38:16Z","timestamp":1646599096000},"page":"1406","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy"],"prefix":"10.3390","volume":"11","author":[{"given":"Piero","family":"Colombatto","sequence":"first","affiliation":[{"name":"Hepatology Unit, Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Palmisano","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7916-5080","authenticated-orcid":false,"given":"Gabriele","family":"Ricco","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cavallone","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9794-7203","authenticated-orcid":false,"given":"Filippo","family":"Oliveri","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Coco","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9779-2731","authenticated-orcid":false,"given":"Antonio","family":"Salvati","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Romagnoli","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3985-3516","authenticated-orcid":false,"given":"Lidia","family":"Surace","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialinda","family":"Vatteroni","sequence":"additional","affiliation":[{"name":"Virology Unit, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0908-6253","authenticated-orcid":false,"given":"Mauro","family":"Pistello","sequence":"additional","affiliation":[{"name":"Virology Unit, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Virdis","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9942-0328","authenticated-orcid":false,"given":"Ferruccio","family":"Bonino","sequence":"additional","affiliation":[{"name":"Institute of Biostructure and Bioimaging, National Research Council, 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-9152","authenticated-orcid":false,"given":"Maurizia Rossana","family":"Brunetto","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, 56124 Pisa, Italy"},{"name":"Institute of Biostructure and Bioimaging, National Research Council, 80145 Naples, Italy"},{"name":"Internal Medicine, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022, February 28). Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240027077."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.22951","article-title":"Hepatitis B and C virus coinfection: A novel model system reveals the absence of direct viral interference","volume":"50","author":"Bellecave","year":"2009","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Shih, Y.-F., and Liu, C.-J. (2020). Hepatitis C Virus and Hepatitis B Virus Co-Infection. Viruses, 12.","DOI":"10.3390\/v12070741"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"710.e1","DOI":"10.1016\/j.cmi.2015.03.003","article-title":"Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-\u03b3-induced protein 10 levels in HBV\/HCV-coinfected patients","volume":"21","author":"Wiegand","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"105061","DOI":"10.1016\/j.antiviral.2021.105061","article-title":"A novel cell culture model reveals the viral interference during hepatitis B and C virus coinfection","volume":"189","author":"Zhang","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1172\/JCI135616","article-title":"Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection","volume":"130","author":"Cheng","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/jvh.13298","article-title":"Characteristics of regulatory T-cell function in patients with chronic hepatitis B and C coinfection","volume":"27","author":"Tseng","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41598-020-57603-9","article-title":"Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway","volume":"10","author":"Murai","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jhep.2014.06.035","article-title":"Innate and adaptive immune responses in HCV infections","volume":"61","author":"Heim","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hep.29135","article-title":"Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals","volume":"66","author":"Belperio","year":"2017","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/jvh.12754","article-title":"HBV reactivation in patients with HCV\/HBV cirrhosis on treatment with direct-acting antivirals","volume":"25","author":"Calvaruso","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jvh.12784","article-title":"Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort","volume":"25","author":"Serper","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: A systematic review and meta-analysis","volume":"3","author":"Coppola","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"792","DOI":"10.7326\/M17-0377","article-title":"Hepatitis B Virus Reactivation Associated with Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System","volume":"166","author":"Cao","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijid.2018.11.014","article-title":"Severe hepatitis B reactivation during direct-acting antiviral treatment in \u201cthe absence\u201d of hepatitis B surface antigen","volume":"79","author":"Sastre","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/infdis\/jiy648","article-title":"Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B\/C Dual-Infected Patients","volume":"219","author":"Yeh","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jhep.2020.01.027","article-title":"Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV\/HCV co-infection","volume":"73","author":"Yeh","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: Final update of the series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"AASLD-IDSA Hepatitis C Guidance Panel (2019). Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection AASLD-IDSA Hepatitis C Guidance Panel. Hepatology, 71, 686\u2013721.","DOI":"10.1002\/hep.31060"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/hepr.13503","article-title":"Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update","volume":"50","author":"Tanaka","year":"2020","journal-title":"Hepatol. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2020.03.010","article-title":"DAAs and HBV\/HCV coinfection: Glimmer of light and a few shades of grey","volume":"73","author":"Roy","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1172\/JCI137477","article-title":"When viruses collide: Hepatitis B virus reactivation after hepatitis C treatment","volume":"130","author":"Balagopal","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/hep.27971","article-title":"Temporal dynamics of inflammatory cytokines\/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection","volume":"62","author":"Carlin","year":"2015","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/liv.13416","article-title":"Long-term outcome of inactive and active, low viraemic HBe, Ag-negative-hepatitis B virus infection: Benign course towards HBs, Ag clearance","volume":"37","author":"Oliveri","year":"2017","journal-title":"Liver Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.14309\/ajg.0000000000000400","article-title":"Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia","volume":"114","author":"Zhou","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of Hepatocellular Carcinoma across a Biological Gradient of Serum Hepatitis B Virus DNA Level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"ref_27","first-page":"155","article-title":"Impact of gender, viral transmission and aging in the preva-lence of hepatitis B surface antigen","volume":"32","author":"Tsay","year":"2009","journal-title":"Chang Gung Med. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3851\/IMP1621","article-title":"The natural history of chronic HBV infection and geographical differences","volume":"15","author":"Liaw","year":"2010","journal-title":"Antivir. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/jgh.12934","article-title":"Gender disparity in chronic hepatitis B: Mechanisms of sex hormones","volume":"30","author":"Wang","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.2169\/internalmedicine.7337-21","article-title":"Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C","volume":"60","author":"Sato","year":"2021","journal-title":"Intern. Med."},{"key":"ref_31","unstructured":"(2022, January 22). Ledipasvir\/Sofosbuvir for Hepatitis B Virus Infection (APOSTLE), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03312023."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/hep.20614","article-title":"Acute phase HBV-specific T cell responses associated with HBV persistence after HBV\/HCV coinfection","volume":"41","author":"Urbani","year":"2005","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jhep.2014.05.043","article-title":"Restoration of HCV-specific CD8+ T cell function by interferon-free therapy","volume":"61","author":"Martin","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1053\/j.gastro.2009.08.066","article-title":"Natural Killer Cells Are Polarized Toward Cytotoxicity in Chronic Hepatitis C in an Interferon-Alfa\u2013Dependent Manner","volume":"138","author":"Ahlenstiel","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.gastro.2015.03.004","article-title":"Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function","volume":"149","author":"Serti","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jhep.2020.05.020","article-title":"Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E\u2014The Hep, Net Sof, E pilot study","volume":"73","author":"Cornberg","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_37","first-page":"558","article-title":"Harvoni: A Combination Therapy for Curing HCV","volume":"Volume 8","author":"Chackalamannil","year":"2017","journal-title":"Comprehensive Medicinal Chemistry III"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1128\/AAC.01922-15","article-title":"Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus","volume":"60","author":"Feng","year":"2016","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/5\/1406\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:31:50Z","timestamp":1760135510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/5\/1406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["jcm11051406"],"URL":"https:\/\/doi.org\/10.3390\/jcm11051406","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]}}}